J
Juno Therapeutics
Is a clinical-stage company, develops immunotherapies for the treatment of cancer
At a glance
- Founded
- 2013
- Headquarters
- Seattle, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Juno Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Bezos Expeditions
Venrock- AFAlaska Permanent Fund
ARCH Venture Partners
Source: Dealroom Talent Intelligence.
Alumni founders
Former Juno Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
XTXaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
UBUmoja BiopharmaEst. 2019
Maddie WilliamsUnited States
OPOnQuality PharmaceuticalsEst. 2018
HONG TANG, MD, FACPChinaGlobal footprint
team presence
across markets
Patents
174 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Juno Therapeutics was the backer or acquirer, 2015–2020. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
6 deals across Juno Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Juno Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Juno Therapeutics's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Juno Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Juno Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.